3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Ovarian Epithelial
5
Melanoma
3
Lymphoma
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Large-Cell, Anaplastic
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Mastocytosis, Systemic
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Mast-Cell
1
Kidney Neoplasms
1
Immunoblastic Lymphadenopathy
1
Colorectal Neoplasms
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
denileukin diftitox
×
Clear all
NCT00801918
2013-05-15
Denileukine Diftitox for Relapsed ALCL
Columbia University
Phase 2
Withdrawn